Valeant Considers Asset Sale to Combat Debt

Source: Bloomberg

May 19, 2016

Currently $30 billion in debt, Valeant Pharmaceuticals is exploring the sale of some of its smaller cosmetic and pharmaceutical assets, says Bloomberg sources.

Sources say Obagi Medical Products, a struggling dermatology company Valeant acquired in 2013, as well as Provenge, a prostate-cancer vaccine purchased last year from Dendreon, and drugs acquired from Marathon Pharmaceuticals are all on the chopping block.

The divestitures could raise as much as $1 billion. According to Bloomberg columist Max Nisen, "That may be wishful thinking. This list includes toxic assets from an already pretty toxic company."

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments